OrthoPediatrics: Options Hedge Up, Sellers Still Heavy Before Tuesday Print

OrthoPediatrics Corp. arrives at Tuesday's earnings release with options positioning that has shifted more defensive in the final days, even as the stock posts its strongest monthly run since early 2026.

The options signal is the freshest development. The put/call ratio has climbed to 0.44, nearly two standard deviations above its 20-day average of 0.25. That is the highest defensive tilt recorded in the recent window, and it arrived precisely as the stock rallied 11.6% over the past week to close at $24.50. Investors willing to chase the move are simultaneously paying up for downside protection, a combination that suggests caution rather than conviction behind the weekly gain. The borrow market offers no additional pressure: availability is extremely loose at 1,476%, borrowing costs have fallen sharply to 0.50% from above 2% earlier in October, and short interest has drifted lower to 3.5% of the free float. There is no short-squeeze dynamic at work here.

The insider picture, documented in yesterday's note, has not changed materially. Squadron Capital, director David R. Pelizzon, and Jennifer Pritzker collectively offloaded more than 660,000 shares across multiple September tranches, with net insider selling of 2.1 million shares and nearly $47 million in proceeds over the past 90 days. None of those trades were executed under a 10b5-1 pre-arranged plan. Pelizzon holds an active Schedule 13D filing, meaning this is a disclosed activist-adjacent holder trimming discretionarily from the top of the register. Squadron's most recent reported institutional position still stands at 6.2 million shares, roughly 24% of the company, so the stake remains dominant even after the reductions. The activist disclosure caveat applies: positions are as-last-reported and the register may not reflect moves below the 5% threshold.

The analyst community leans constructive. The consensus is Buy, with a mean price target of $27.50 against a current price of $24.50, implying roughly 12% upside. BTIG reiterated its Buy rating in September with a $29 target, and after the Q1 beat in August, Needham raised its target to $35. The bull case centres on OrthoPediatrics' so-called "Super Cycle" of product launches across trauma, scoliosis, and bracing, plus 13.3% year-over-year revenue growth in Q1 and full-year guidance of $263 million to $267 million. Bears flag distributor execution risk, competition from larger orthopedic players, and the still-negative earnings yield: the trailing PE sits at roughly negative 31 times, and the company is not yet generating positive net income. At an EV/EBITDA of around 20 times, the valuation leaves limited room for a guidance miss. The two most recent prints produced one-day gains of 3.4% and 6.9% respectively, with five-day moves of 15% and 16% in both cases, suggesting the stock has historically rewarded beats emphatically.

Tuesday's print will test whether the Q2 revenue pace can maintain that double-digit trajectory, and whether management's profitability roadmap is advancing fast enough to justify a stock that has re-rated sharply higher even as its largest insiders have been persistent sellers.